Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00086216
Recruitment Status : Completed
First Posted : June 30, 2004
Last Update Posted : December 21, 2007
Information provided by:
Callisto Pharmaceuticals

Brief Summary:
This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Atiprimod Phase 1 Phase 2

Detailed Description:
This is a multi-center, open-label, dose escalation study intended to identify the MTD of atiprimod alone and the MTD of atiprimod when given in combination with ursodiol. The atiprimod dose will be escalated in sequential cohorts. Ten dose levels of atiprimod are planned for the atiprimod alone dose escalation: 30, 60, 90, 120, 180, 240, 300, 360, 420, and 480 mg/day to be given orally. Six dose levels of atiprimod are planned for the atiprimod in combination with ursodiol dose escalation: 180, 240, 300, 360, 420, and 480 mg/day to be given orally. The dose of ursodiol will remain constant for all cohorts (300 mg ursodiol orally three times a day everyday). Up to 105 patients will participate depending on the level at which toxicity is observed. Patients will be assigned to dose level in the order of study entry.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma
Study Start Date : May 2004
Actual Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Intervention Details:
  • Drug: Atiprimod
    Oral, once a day, 14 days on 14 days off

Primary Outcome Measures :
  1. The primary objective of this study is to identify the maximum tolerated dose [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. The secondary objective of this study is to measure the pharmacokinetics of [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • documented history of multiple myeloma,
  • failed at least two prior regimens for multiple myeloma,
  • 18 years of age or older,
  • ECOG(Zubrod)PS of 0 to 2,
  • screening evaluation for determining eligibility prior to enrollment,
  • signed informed consent form,

Exclusion Criteria:

  • concomitant therapy medications including corticosteroids or other chemotherapy that is or may be active against myeloma ,
  • renal insufficiency (serum creatinine levels of > 2mg/dL),
  • mucosal bleeding,
  • any condition which in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study.
  • clinically relevant active infection or co-morbid medical conditions.
  • prior malignancy(within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient is has been disease-free for at least 3 years.
  • patients with non-secretory myeloma.
  • as atiprimod is a potent inhibitor or CYP2D6, patients taking drugs that are substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics) will be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00086216

Layout table for location information
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Callisto Pharmaceuticals
Layout table for investigator information
Study Director: Gary Jacob, PhD Callisto Pharmaceuticals
Layout table for additonal information
Responsible Party: Gary Jacob, Callisto Pharmaceuticals Identifier: NCT00086216    
Obsolete Identifiers: NCT00301977, NCT00491972
Other Study ID Numbers: CP-101
research markers
First Posted: June 30, 2004    Key Record Dates
Last Update Posted: December 21, 2007
Last Verified: December 2007
Keywords provided by Callisto Pharmaceuticals:
Multiple myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases